Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5598-5604

  Lake, Sarah L ^a   Jmor, Fidan ^a   Dopierala, Justyna ^a   Taktak, Azzam F G ^b   Coupland, Sarah E ^a   Damato, Bertil E ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLUTAMIC ACID; TRANSCRIPTION FACTOR RUNX2; VALINE; BRAF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAF GENE; CLINICAL ARTICLE; CONJUNCTIVA TUMOR; CONJUNCTIVAL MELANOMA; CONTROLLED STUDY; COPY NUMBER VARIATION; DEATH; FEMALE; GENE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL; DNA PROBE; GENE DOSAGE; GENETIC PREDISPOSITION; GENETICS; MELANOMA; METHODOLOGY; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION; PATHOLOGY; POINT MUTATION; PROGNOSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CONJUNCTIVAL NEOPLASMS; DNA PROBES; FEMALE; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; YOUNG ADULT;

EID: 80053300050     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6934     Document Type: Article

References (72)

1. Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998;42: 321-350.
2. Shields CL. Conjunctival melanoma. Br J Ophthalmol. 2002;86:127.
3. Scotto J, Fraumeni JF Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst. 1976;56:489-491.
4. Missotten GS, Keijser S, De Keizer RJ, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005;46:75-82.
5. Tuomaala S, Eskelin S, Tarkkanen A, Kivela T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43:3399-3408.
6. Shields CL. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc. 2000;98:471-492.
7. Silvers D, Jakobiec FA, Freeman T, et al. Melanoma of the conjunctiva: a clinicopathologic study. In: Jakobiec FA, ed. Ocular and Adnexal Tumors. Birmingham, UK: Aesculapius; 1978:583-599.
8. Damato B, Coupland SE. Clinical mapping of conjunctival melanomas. Br J Ophthalmol. 2008;92:1545-1549.
9. Damato B, Coupland SE. Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Exp Ophthalmol. 2008;36:786-795.
10. de Wolff-Rouendaal D. Melanozytar̈e tumoren der bindehaut. In: Lommatzsch P, ed. Ophthalmologische onkologie. Stuttgart, Germany: Enke; 1990:81-95.
11. Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl KP. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol. 2002;86:163-167.
12. Desjardins L, Poncet P, Levy C, Schlienger P, Asselain B, Validire P. [Prognostic factors in malignant melanoma of the conjunctiva: an anatomo-clinical study of 56 patients]. J Fr Ophtalmol. 1999;22: 315-321.
13. Tuomaala S, Kivela T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmology. 2004;111:816-821.
14. Damato B, Coupland SE. An audit of conjunctival melanoma treatment in Liverpool. Eye (Lond). 2009;23:801-809.
15. Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS. BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res. 2004;14:449-452.
16. Gear H, Williams H, Kemp EG, Roberts F. BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci. 2004;45: 2484-2488.
17. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
18. Goldenberg-Cohen N, Cohen Y, Rosenbaum E, et al. T1799A BRAF mutations in conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci. 2005;46:3027-3030.
19. Brownstein S. Malignant melanoma of the conjunctiva. Cancer Control. 2004;11:310-316.
20. Vajdic CM, Hutchins AM, Kricker A, et al. Chromosomal gains and losses in ocular melanoma detected by comparative genomic hybridization in an Australian population-based study. Cancer Genet Cytogenet. 2003;144:12-17.
21. Busam KJ, Fang Y, Jhanwar SC, Pulitzer MP, Marr B, Abramson DH. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization. J Cutan Pathol. 2010;37:196-203.
22. Dahlenfors R, Tornqvist G, Wettrell K, Mark J. Cytogenetical observations in nine ocular malignant melanomas. Anticancer Res. 1993;13:1415-1420.
23. McNamara M, Felix C, Davison EV, Fenton M, Kennedy SM. Assessment of chromosome 3 copy number in ocular melanoma using fluorescence in situ hybridization. Cancer Genet Cytogenet. 1997;98:4-8.
24. Sinilnikova OM, Egan KM, Quinn JL, et al. Germline brca2 sequence variants in patients with ocular melanoma. Int J Cancer. 1999;82:325-328.
25. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010;16:6083-6092.
26. Dratviman-Storobinsky O, Cohen Y, Frenkel S, Pe'er J, Goldenberg-Cohen N. Lack of oncogenic GNAQ mutations in melanocytic lesions of the conjunctiva as compared to uveal melanoma. Invest Ophthalmol Vis Sci. 2010;51:6180-6182.
27. Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114:1925-1931.
28. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222-1225.
29. Mensink HW, Kilic E, Vaarwater J, Douben H, Paridaens D, de Klein A. Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome. Cancer Genet Cytogenet. 2008;181: 108-111.
30. Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46:2253-2257.
31. Damato B. Legacy of the collaborative ocular melanoma study. Arch Ophthalmol. 2007;125:966-968.
32. Cook SA, Damato B, Marshall E, Salmon P. Psychological aspects of cytogenetic testing of uveal melanoma: preliminary findings and directions for future research. Eye (Lond). 2009;23:581-585.
33. Lake SL, Coupland SE, Taktak AF, Damato BE. Whole-genome microarray detects deletions and loss of heterozygosity of chromosome3 occurring exclusively in metastasizing uveal melanoma. Invest Ophthalmol Vis Sci. 2010;51:4884-4891.
34. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
35. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci. 2009;50:3048-3055.
36. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:313-317.
37. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer. 1998;83:354-359.
38. Aubert C, Rouge F, Reillaudou M, Metge P. Establishment and characterization of human ocular melanoma cell lines. Int J Cancer. 1993;54:784-792.
39. Namiki T, Yanagawa S, Izumo T, et al. Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet Cytogenet. 2005;157:1-11.
40. Pirker C, Holzmann K, Spiegl-Kreinecker S, et al. Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res. 2003;13:483-492.
41. Koynova DK, Jordanova ES, Milev AD, et al. Gene-specific fluorescence in-situ hybridization analysis on tissue microarray to refine the region of chromosome 20q amplification in melanoma. Melanoma Res. 2007;17:37-41.
42. Packer LM, Pavey SJ, Boyle GM, et al. Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF. Int J Cancer. 2007;121:784-790.
43. Jiang H, Lin J, Su ZZ, et al. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene. 1995;10:1855-1864.
44. Riminucci M, Corsi A, Peris K, Fisher LW, Chimenti S, Bianco P. Coexpression of bone sialoprotein (BSP) and the pivotal transcriptional regulator of osteogenesis, Cbfa1/Runx2, in malignant melanoma. Calcif Tissue Int. 2003;73:281-289.
45. Baniwal SK, Khalid O, Gabet Y, et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer. 2010;9:258.
46. Leong DT, Lim J, Goh X, et al. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res. 2010;12:R89.
47. Mohammad KS, Javelaud D, Fournier PG, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 2011;71:175-184.
48. de Keizer PL, Packer LM, Szypowska AA, et al. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. Cancer Res. 2010;70:8526-8536.
49. Park KS, Kim SJ, Kim KH, Kim JC. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2011;26:391-397.
50. Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol. 2006;6:19.
51. Gentner B, Wein A, Croner RS, et al. Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res. 2009;29:67-74.
52. Mendes O, Kim HT, Lungu G, Stoica G. MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis. 2007;24:341-351.
53. Pancione M, Forte N, Fucci A, et al. Prognostic role of beta-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Hum Pathol. 2010;41:867-876.
54. Guan H, Ji M, Hou P, et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer. 2008;113:247-255.
55. Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA, van der Velden PA. Epigenetic regulation identifies RASEF as a tumorsuppressor gene in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:1291-1298.
56. Onken MD, Worley LA, Harbour JW. A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin Cancer Res. 2008;14:3737-3745.
57. Zeschnigk M, Tschentscher F, Lich C, Brandt B, Horsthemke B, Lohmann DR. Methylation analysis of several tumour suppressor genes shows a low frequency of methylation of CDKN2A and RARB in uveal melanomas. Comp Funct Genomics. 2003;4:329-336.
58. Myong NH. Role of Loss of O-methylguanine DNA methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression. Cancer Res Treat. 2010;42:95-100.
59. Voelter V, Diserens AC, Moulin A, et al. Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. Int J Cancer. 2008;123:1215-1218.
60. Funari MF, Jorge AA, Souza SC, et al. Usefulness of MLPA in the detection of SHOX deletions. Eur J Med Genet. 2010;53:234-238.
61. Cabello MJ, Grau L, Franco N, et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn. 2011;13:29-40.
62. Conway C, Beswick S, Elliott F, et al. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer. 2011;49:425-438.
63. Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res. 2011;17:2055-2064.
64. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164: 776-7840.
65. Ellerhorst JA, Greene VR, Ekmekcioglu S, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2010;17:229-235.
66. Goldstein NS. Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. Am J Clin Pathol. 2006;125:146-153.
67. Broekaert SM, Roy R, Okamoto I, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 2010;23:763-770.
68. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483-6488.
69. Laud K, Kannengiesser C, Avril MF, et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res. 2003;63:3061-3065.
70. Meyer P, Klaes R, Schmitt C, Boettger MB, Garbe C. Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int J Cancer. 2003;106:78-80.
71. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95: 1878-1890.
72. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363: 809-819.